Abstract: Newly discovered alternative transcripts of the KLK8 gene encoding kallikrein 8, NT5 and NT6. The sequence of NT5 is set forth in SEQ ID NO:7, and the sequence of NT6 is set forth in SEQ ID NO:8.

Abstract: Newly discovered alternative transcripts of the KLK8 gene encoding kallikrein 8, NT5 and NT6. The sequence of NT5 is set forth in SEQ ID NO:7, and the sequence of NT6 is set forth in SEQ ID NO:8.

Abstract: A method for the in vitro diagnosis of bronchopulmonary carcinoma, in particular of non-small cell bronchial carcinoma, that includes a stage of detecting, in a biological sample derived from a patient suspected to be suffering from bronchopulmonary carcinoma, at least one of the major alternative transcripts of the KLK8 gene encoding kallikrein 8. This method is particularly useful for the survival prognostication of patients suffering from bronchopulmonary carcinoma.

Abstract: A method for the in vitro diagnosis of bronchopulmonary carcinoma, in particular of non-small cell bronchial carcinoma, that includes a stage of detecting, in a biological sample derived from a patient suspected to be suffering from bronchopulmonary carcinoma, at least one of the major alternative transcripts of the KLK8 gene encoding kallikrein 8. This method is particularly useful for the survival prognostication of patients suffering from bronchopulmonary carcinoma.

Abstract: The present invention relates to a method for the in vitro diagnosis of bronchopulmonary carcinoma, in particular of non-small cell bronchial carcinoma, characterized in that it comprises the stage of detecting, in a biological sample derived from a patient suspected to be suffering from said bronchopulmonary carcinoma, at least one of the major alternative transcripts of the KLK8 gene encoding kallikrein 8. This method is particularly useful for the survival prognostication of patients suffering from bronchopulmonary carcinoma.

Abstract: New conformational antibodies are directed against HCV and more particularly to monoclonal antibodies. Described compositions of particles are liable to be recognized by the antibodies, as are pharmaceutical compositions containing them. Also described are HCV enveloped subviral particles or purified HCV enveloped complete viral particles, and the processes for preparing them.

Abstract: Viral material, in the isolated or purified state, in which the genome comprises a nucleotide sequence chosen from the group including sequences SEQ ID NO:46, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53 and SEQ ID NO:56, their complementary sequences and their equivalent sequences, in particular nucleotide sequences displaying, for any succession of 100 contiguous monomers, at least 50% and preferably at least 70% homology with the said sequences SEQ ID NO:46, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53 and SEQ ID NO:56, respectively, and their complementary sequences.

Abstract: The present invention relates to the use of at least one partner for binding to an aldehyde derivative resulting from the peroxidation of lipids in protein-bound form, for instance to 4-hydroxy-2-nonenal, to 4-hydroxy-2-hexenal or to malondialdehyde, for the detection of ischemia-modified albumin (IMA) in a biological sample.

Abstract: The present invention relates to a method for the in vitro diagnosis of bronchopulmonary carcinoma, in particular of non-small cell bronchial carcinoma, characterized in that it comprises the stage of detecting, in a biological sample derived from a patient suspected to be suffering from said bronchopulmonary carcinoma, at least one of the major alternative transcripts of the KLK8 gene encoding kallikrein 8. This method is particularly useful for the survival prognostication of patients suffering from bronchopulmonary carcinoma.

Abstract: The present invention relates to a monoclonal antibody capable of binding to a wild-type HBsAg antigen and to at least one, preferably at least two and advantageously more than two, mutant forms of the HBsAg antigen, said monoclonal antibody binding to a peptide sequence consisting of at least 6 contiguous amino acids in the 199-208 region of the HBsAg antigen, and advantageously binding to the peptide sequence constituted by the 199-208 region of the HBsAg antigen.

Abstract: The invention provides viral material and nucleotide fragments associated with multiple sclerosis and/or rheumatoid arthritis for use in method of diagnosis, prophylaxis, and therapy.

Abstract: New conformational antibodies are directed against HCV and more particularly to monoclonal antibodies. Described compositions of particles are liable to be recognized by the antibodies, as are pharmaceutical compositions containing them. Also described are HCV enveloped subviral particles or purified HCV enveloped complete viral particles, and the processes for preparing them.

Abstract: Isolated HXHV virus having the following characteristics: (i) a DNA genome which is at least partially single-stranded, (ii) the said genome comprises one reading frame (ORF) encoding one protein or one polyprotein (iii) the said genome comprises a nucleotide sequence which exhibits, for any segment of at least 40 nucleotides belonging to the said sequence, at least 90% homology with SEQ ID NO: 1 or with its complementary sequence, nucleic material and peptide material and uses.

Abstract: The present invention relates to a method for the in vitro diagnosing of a benign pathology of the prostate or of an adenocarcinoma of the prostate, characterized in that it comprises the step consisting of detection, in a biological sample from a patient suspected of suffering from a benign pathology of the prostate or from an adenocarcinoma of the prostate, of the activatable free form of PSA.

Abstract: Viral material, in the isolated or purified state, in which the genome comprises a nucleotide sequence chosen from the group including sequences SEQ ID NO:46, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53 and SEQ ID NO:56, their complementary sequences and their equivalent sequences, in particular nucleotide sequences displaying, for any succession of 100 contiguous monomers, at least 50% and preferably at least 70% homology with the said sequences SEQ ID NO:46, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53 and SEQ ID NO:56, respectively, and their complementary sequences.

Abstract: The invention provides viral material and nucleotide fragments associated with multiple sclerosis and/or rheumatoid arthritis for use in method of diagnosis, prophylaxis, and therapy.

Abstract: New conformational antibodies are directed against HCV and more particularly to monoclonal antibodies. Described compositions of particles are liable to be recognized by the antibodies, as are pharmaceutical compositions containing them. Also described are HCV enveloped subviral particles or purified HCV enveloped complete viral particles, and the processes for preparing them.

Abstract: An immunoassay for the quantitative determination of inactive, non-zymogen, free PSA in a biological sample taken from an individual, including contacting the biological sample with a reagent, where the reagent comprises an antibody or antibody fragments that bind specifically to inactive, non-zymogen, free PSA, the antibody being a purified polyclonal antibody or a monoclonal antibody, and evaluating the amount of inactive, non-zymogen, free PSA bound to the antibodies or antibody fragments.

Abstract: An oligopeptides comprising the following sequence Thr Gln Cys His Cys Gly Lys Cys (SEQ ID NO: 5) may be used as an antigenic compound capable of being recognized by anti-ovary antibodies and as an immunogenic compound capable of inducing the production of anti-ovary antibodies. In addition, the oligopeptides may be used to detect and/or quantify anti-ovary antibodies.

Abstract: The invention concerns an artificial antigen specifically identified by the anti-filaggrin autoantibodies present in the serum of patients suffering from rheumatoid polyarthritis, and consisting of one polypeptide comprising all or part of the sequence of one filaggrin unit or of a related molecule, in which an arginine radical has been substituted by a citrulline radical. The invention also concerns the use of this antigen for diagnosing rheumatoid polyarthritis.